Sanara Medtech | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 28.14 M
I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q2, the actual value is USD 28.14 M, missing the estimate of USD 28.95 M.
EPS: As of FY2026 Q2, the actual value is USD -0.05.
EBIT: As of FY2026 Q2, the actual value is USD 3.537 M.
Second Quarter 2026 Financial Summary
Net Revenue
Sanara MedTech Inc. reported net revenue of $28.1 million for the second quarter of 2026, an increase of 9% compared to $25.8 million in the second quarter of 2025.
Gross Profit and Margin
Gross profit for the second quarter of 2026 was $26.2 million, or 93% of net revenue, up from $23.9 million, or 92% of net revenue, in the second quarter of 2025.
Operating Income
Operating income for the second quarter of 2026 was $1.8 million, a decrease from $2.5 million in the second quarter of 2025.
Net Income (Loss) from Continuing Operations
Net loss from continuing operations was -$0.4 million, or a loss of -$0.05 per diluted share, for the second quarter of 2026, compared to net income of $0.5 million, or $0.05 per diluted share, in the second quarter of 2025.
Adjusted EBITDA
Adjusted EBITDA was $5.0 million for the second quarter of 2026, an increase from $4.7 million in the second quarter of 2025.
Operating Expenses
Operating expenses increased by 14% to $24.4 million, or 86.8% of net revenue, in the second quarter of 2026, compared to $21.4 million, or 82.9% of net revenue, in the second quarter of 2025. Selling, general, and administrative (SG&A) expenses were $22,601,690 in Q2 2026, up from $19,634,319 in Q2 2025. Research and development (R&D) expenses increased to $1,154,232, or 4% of net revenue, in Q2 2026, from $1,056,796, or 4% of net revenue, in Q2 2025.
Other Expense
Other expense for the second quarter of 2026 was -$2.2 million, compared to -$2.0 million for the second quarter of 2025.
Net Income (Loss) from Discontinued Operations
Net loss from discontinued operations was -$41,720 for the second quarter of 2026, a significant improvement from a net loss of -$2.5 million in the second quarter of 2025.
First Six Months of 2026 Financial Summary
Net Revenue
Net revenue for the first six months of 2026 increased 14% to $55.9 million, compared to $49.2 million in the first six months of 2025.
Gross Profit and Margin
Gross profit for the first six months of 2026 was $52.0 million, or 93% of net revenue, compared to $45.5 million, or 92% of net revenue, in the first six months of 2025.
Operating Income
Operating income for the first six months of 2026 was $4.4 million, up from $3.3 million in the first six months of 2025.
Net Income (Loss) from Continuing Operations
Net loss from continuing operations for the first six months of 2026 was -$13,457, or zero per diluted share, compared to a net loss of -$0.1 million, or -$0.01 per diluted share, in the first six months of 2025.
Adjusted EBITDA
Adjusted EBITDA for the first six months of 2026 was $9.3 million, an increase from $7.4 million in the first six months of 2025.
Operating Expenses
Operating expenses for the first six months of 2026 were $47.6 million, or 85.2% of net revenue, compared to $42.2 million, or 85.8% of net revenue, for the first six months of 2025. SG&A expenses were $44,483,210 for the first six months of 2026, up from $38,763,527 in the prior-year period. R&D expenses decreased to $1,913,824, or 3% of net revenue, from $2,007,155, or 4% of net revenue, in the first six months of 2025.
Other Expense
Other expense for the first six months of 2026 was -$4.4 million, compared to -$3.4 million for the first six months of 2025.
Net Income (Loss) from Discontinued Operations
Net income from discontinued operations for the first six months of 2026 was $19,196, compared to a net loss of -$5.4 million for the first six months of 2025.
Segment Revenue
Second Quarter 2026 Segment Revenue
Soft tissue repair product sales increased by $2.5 million, or 11%, to $25,242,592 in the second quarter of 2026, from $22,661,457 in the second quarter of 2025. Sales of bone fusion products decreased by -$0.2 million, or 8%, to $2,894,165 in the second quarter of 2026, from $3,142,795 in the second quarter of 2025.
First Six Months 2026 Segment Revenue
Soft tissue repair product sales increased by $7.0 million, or 16%, to $50,185,537 in the first six months of 2026, from $43,193,897 in the first six months of 2025. Sales of bone fusion products decreased by -$0.3 million, or 5%, to $5,749,754 in the first six months of 2026, from $6,044,451 in the first six months of 2025.
Cash Flow
Net cash used in operating activities for the first six months of 2026 was -$0.4 million, a change from $0.7 million of net cash provided by operating activities in the first six months of 2025.
Balance Sheet Highlights
As of June 30, 2026, Sanara MedTech Inc. had $15.4 million in cash and cash equivalents, compared to $16.6 million at December 31, 2025. Long-term debt stood at $46.5 million as of June 30, 2026, slightly up from $46.0 million at December 31, 2025.
Outlook / Guidance
Sanara MedTech Inc. announced an agreement for its acquisition by MIMEDX, aiming to combine their surgical focus and technologies with MIMEDX’s surgical portfolio. The transaction is expected to deepen existing distributor relationships and expand operating presence by integrating the two organizations. Additionally, Sanara MedTech Inc. plans to introduce OsStic, a licensed synthetic injectable structural bio-adhesive bone void filler, to the market in the first quarter of 2027.